Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
43
FLGT Quote, Financials, Valuation and Earnings
Last price:
$27.05
Seasonality move
:
14.15%
Day range:
$26.75 - $27.14
52-week range:
$14.57 - $31.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.63x
P/B ratio:
0.74x
Volume:
121.8K
Avg. volume:
288.8K
1-year change:
45.92%
Market cap:
$834.9M
Revenue:
$283.5M
EPS (TTM):
-$1.40
Analysts' Opinion
-
Consensus RatingFulgent Genetics, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.67, Fulgent Genetics, Inc. has an estimated upside of 24.65% from its current price of $27.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing -11.07% downside risk from its current price of $27.01.
Fair Value
-
According to the consensus of 2 analysts, Fulgent Genetics, Inc. has 24.65% upside to fair value with a price target of $33.67 per share.
FLGT vs. S&P 500
-
Over the past 5 trading days, Fulgent Genetics, Inc. has underperformed the S&P 500 by -3.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fulgent Genetics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fulgent Genetics, Inc. has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Fulgent Genetics, Inc. reported revenues of $84.1M.
Earnings Growth
-
Fulgent Genetics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Fulgent Genetics, Inc. reported earnings per share of -$0.21.
Enterprise value:
462M
EV / Invested capital:
0.41x
Price / LTM sales:
2.63x
EV / EBIT:
--
EV / Revenue:
1.46x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-23.28x
Price / Operating cash flow:
57.70x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$122.1M
Return On Assets:
-3.61%
Net Income Margin (TTM):
-14%
Return On Equity:
-3.93%
Return On Invested Capital:
-3.9%
Operating Margin:
-18.26%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $286.4M | $277.8M | $315.5M | $71.7M | $84.1M | |
| Gross Profit | $84.3M | $92.7M | $122.1M | $24.8M | $33.5M | |
| Operating Income | -$81M | -$88.7M | -$71M | -$17.1M | -$15.4M | |
| EBITDA | -$45.7M | -$63.4M | -$46.8M | -$11.2M | -$9.3M | |
| Diluted EPS | -$2.14 | -$5.53 | -$1.40 | -$0.48 | -$0.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $622.8M | $696.6M | $549.9M | $326.5M | $507.4M | |
| Total Assets | $1.2B | $1.4B | $1.4B | $1.2B | $1.2B | |
| Current Liabilities | $147.2M | $102.5M | $61.4M | $74M | $72.4M | |
| Total Liabilities | $160.2M | $124.4M | $96.6M | $98.9M | $93.8M | |
| Total Equity | $1B | $1.3B | $1.3B | $1.1B | $1.1B | |
| Total Debt | $11.7M | $17.8M | $13.4M | $8.5M | $6.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $45.3M | $11M | $1.5M | -$15.5M | $11.1M | |
| Cash From Investing | -$78M | -$6.6M | $72.8M | $9M | $19.1M | |
| Cash From Financing | -$51.4M | -$30.5M | -$14.6M | -$567K | -$445K | |
| Free Cash Flow | $21.5M | -$28.7M | -$19.8M | -$35M | $5.1M | |
FLGT
Sector
Market Cap
$834.9M
$28.1M
Price % of 52-Week High
87.02%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
1.71%
-1.49%
1-Year Price Total Return
45.92%
-17.13%
Beta (5-Year)
0.648
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$27.38
200-day SMA
Buy
Level
$21.60
Bollinger Bands (100)
Buy
Level
21.26 - 27.24
Chaikin Money Flow
Sell
Level
-12.6M
20-day SMA
Sell
Level
$27.85
Relative Strength Index (RSI14)
Sell
Level
45.46
ADX Line
Sell
Level
16.82
Williams %R
Buy
Level
-80.2057
50-day SMA
Buy
Level
$26.53
MACD (12, 26)
Buy
Level
0.04
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
38.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.6288)
Buy
CA Score
(Annual)
Level (1.1811)
Buy
Beneish M-Score
(Annual)
Level (-2.3599)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.1043)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.
Stock Forecast FAQ
In the current month, FLGT has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The FLGT average analyst price target in the past 3 months is $33.67.
-
Where Will Fulgent Genetics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fulgent Genetics, Inc. share price will rise to $33.67 per share over the next 12 months.
-
What Do Analysts Say About Fulgent Genetics, Inc.?
Analysts are divided on their view about Fulgent Genetics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fulgent Genetics, Inc. is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Fulgent Genetics, Inc.'s Price Target?
The price target for Fulgent Genetics, Inc. over the next 1-year time period is forecast to be $33.67 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is FLGT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fulgent Genetics, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of FLGT?
You can purchase shares of Fulgent Genetics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fulgent Genetics, Inc. shares.
-
What Is The Fulgent Genetics, Inc. Share Price Today?
Fulgent Genetics, Inc. was last trading at $27.05 per share. This represents the most recent stock quote for Fulgent Genetics, Inc.. Yesterday, Fulgent Genetics, Inc. closed at $27.01 per share.
-
How To Buy Fulgent Genetics, Inc. Stock Online?
In order to purchase Fulgent Genetics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FLGT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FLGT
Sector
P/E ratio
--
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
0.74x
1.81x
Price / LTM sales
2.63x
1.59x
Growth Metrics
FLGT
Sector
Revenue growth
17.18%
4.62%
Earnings growth
55.38%
11.06%
Revenue (5-year growth)
54.19%
6.5%
Earnings forecast
-$0.22
-$0.21
Profitability
FLGT
Sector
Profitability FY 2024
$99.3M
$3.6M
Return on invested capital
-3.9%
-31.84%
Return on assets
-3.61%
-27.96%
Return on equity
-3.93%
-37.63%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Feb
27
Estimated Next Earnings Date
Feb
6
Balance Sheet
FLGT
Sector
Total cash
$375.8M
$26.4M
Short term investments
$203M
$25.7M
Total assets
$1.3B
$76.9M
Long term debt
$6.5M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
